SinoMab Bioscience Ltd. is a clinical stage biopharmaceutical company, which engages in the research, development, and manufacture of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody-based biologics. The company employs 61 full-time employees The company went IPO on 2019-11-12. The firm primarily develops mAb-based biologics and new chemical entities (NCE) and its product SM03 is a mAb for the treatment of rheumatoid arthritis (RA). The firm is also developing drugs such as SM17, which has the potential to treat atopic dermatitis (AD), asthma, idiopathic pulmonary fibrosis (IPF) and other immune diseases, and SN1011, which targets systemic lupus erythematosus (SLE), pemphigus, multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD).
03681.HK stock price ended at $1.89 on 星期五, after rising 5.59%
On the latest trading day Feb 13, 2026, the stock price of 03681.HK rose by 5.59%, climbing from $1.77 to $1.89. During the session, the stock saw a volatility of 7.91%, with prices oscillating between a daily low of $1.77 and a high of $1.91. Notably, trading volume dropped by 8.7M shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 13.8M shares were traded, equating to a market value of approximately $2.6B.